US pharmaceutical company Pfizer has reached an agreement with China's Starna Therapeutics to acquire the rights to three experimental CAR-T therapies for the treatment of autoimmune diseases. The initial payment will amount to $330 million, and including additional payments the value of the deal could reach $2.63 billion, excluding royalties.
The deal concerns in vivo technology, which makes it possible to reprogramme immune cells directly inside the patient's body. Starna uses RNA and lipid nanoparticles to deliver the genetic material.
Pfizer receives exclusive rights to develop, manufacture and commercialise the three drugs outside mainland China, Hong Kong, Macau and Taiwan. In future, the US company will be able to extend the licence to this region as well.
In this territory, Pfizer will also organise clinical trials. The first batches of the drugs for these purposes are planned to be produced at the company's manufacturing sites in the United States.
All three developments are still at the preclinical stage.
Current CAR-T therapy involves extracting a patient's immune cells, modifying them in a laboratory and then returning them to the body (ex vivo). In the case of in vivo CAR-T, this stage takes place directly inside the body.
So far, no drug based on in vivo CAR-T has been approved.
Pfizer expects the technology to make it possible to create new treatments for autoimmune diseases for which existing approaches prove insufficiently effective. The company also intends to use its experience in developing RNA-based drugs to advance the acquired programmes.
The agreement provides for the possible use of Starna's technology in immunology and in the treatment of inflammatory and oncological diseases. In addition, Pfizer will be able to obtain exclusive licences for additional compounds created under a separate research collaboration between the companies.
Interest among major pharmaceutical companies in in vivo CAR-T has grown noticeably in 2026. US company Eli Lilly acquired two developers in this field, Kelonia Therapeutics and Orna Therapeutics. Another US company, Kyverna Therapeutics, is awaiting an FDA decision on its application for the first CAR-T therapy to treat an autoimmune disease.
Starna Therapeutics was founded in 2021. In addition to cell technologies, the company is developing anti-tumour mRNA vaccines and a vaccine against respiratory syncytial virus. In May 2026, the start-up raised $44 million in investment.